Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet . 2018 Dec 1;392(10162):2378-2387. doi: 10.1016/S0140-6736(18)32463-2 (2018)
https://pubmed.ncbi.nlm.nih.gov/30360970/